title: Titanium-nitride-oxide coated stents versus paclitaxel-eluting stents in acute myocardial infarction: a 12-months follow-up report from the TITAX AMI trial.
abstract: OBJECTIVE
  The aim of this study was to evaluate the effectiveness of titanium-nitride-oxide (TITANOX)-coated stent and paclitaxel-eluting stent (PES) in patients presenting with acute myocardial infarction (MI).
  
  
  RESULTS
  A total of 425 patients presenting with acute non-ST-elevation MI or ST-elevation MI were randomly assigned to receive TITANOX-coated stent or PES. The primary end point was a composite of MI, target lesion revascularisation (TLR) or death from cardiac causes. At 12 months, there was no significant difference between patients receiving TITANOX-coated stent or PES in the rates of primary end point (10.3% vs. 12.8%, P=0.5), MI (4.2% vs. 8.1%, P=0.1), or TLR (9.3% vs. 7.1%, P=0.5), respectively. The incidence of stent thrombosis, defined according to Academic Research Consortium classification, was significantly lower in the TITANOX group compared to the PES group (0.9% vs. 4.3%, P=0.03).
  
  
  CONCLUSIONS
  TITANOX-coated stent and PES resulted in comparable clinical outcomes during 12 months follow-up among patients treated for acute MI.
authors.affiliation: Department of Cardiology, Satakunta Central Hospital, Pori, Finland. pasi.karjalainen@satshp.fi
authors.forename: Pasi P
authors.initials: PP
authors.lastname: Karjalainen
authors.forename: Antti
authors.initials: A
authors.lastname: Ylitalo
authors.forename: Matti
authors.initials: M
authors.lastname: Niemelä
authors.forename: Kari
authors.initials: K
authors.lastname: Kervinen
authors.forename: Timo
authors.initials: T
authors.lastname: Mäkikallio
authors.forename: Mikko
authors.initials: M
authors.lastname: Pietili
authors.forename: Jussi
authors.initials: J
authors.lastname: Sia
authors.forename: Petri
authors.initials: P
authors.lastname: Tuomainen
authors.forename: Kai
authors.initials: K
authors.lastname: Nyman
authors.forename: K E Juhani
authors.initials: KE
authors.lastname: Airaksinen
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D018572:Disease-Free Survival; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology / Q000628:therapy*; D017239:Paclitaxel / Q000008:administration & dosage*; D012008:Recurrence; D012307:Risk Factors; D013927:Thrombosis / Q000517:prevention & control; D014025:Titanium; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; C434243:titanium-nitride-oxide; D014025:Titanium; D017239:Paclitaxel